We have located links that may give you full text access.
Treatment of myopic astigmatism with the Summit Apex Plus excimer laser.
Journal of Cataract and Refractive Surgery 1997 December
PURPOSE: To assess the results of surface sequential toric photorefractive keratectomy (PRK) with the Summit Apex Plus excimer laser using an erodible mask.
METHODS: A prospective study was performed on consecutive eyes having surface sequential toric PRK over a 4 month treatment period. Attempted astigmatism correction varied from 70 to 100%, depending on the power and axis of the cylinder. The myopic correction was adjusted so the combined treatment aim was emmetropia. Refraction, manual keratometry, corneal haze, and visual acuity data from preoperative and follow-up visits over 12 months were divided into various groups based on the preoperative refraction and analyzed.
RESULTS: Fifty-nine eyes from 48 patients had sequential toric PRK. Preoperatively, the mean spherical equivalent at glasses plane (SEGP) was -4.88 diopters (D) +/- 3.20 (SD) and the mean refractive cylinder, 2.02 +/- 1.04 D. The mean attempted cylinder correction was 1.87 D. At 12 months the mean SEGP was -0.02 +/- 0.67 D, which was not statistically significant from plano. The mean refractive cylinder was 0.84 +/- 0.84 D, which was statistically significantly different from zero cylinder power. There was a statistically significant correlation between the preoperative and the 12 month postoperative refractive cylinder powers. At 12 months, 34 of 43 eyes (79.1%) had an uncorrected visual acuity of 6/12 or better. While 2 eyes in one patient (4.7%) lost two lines of best corrected visual acuity, with a final acuity of 6/12 in each, no patient lost more than two lines.
CONCLUSION: The manifest refraction cylinder power is not fully corrected with the current treatment algorithms; however, surface sequential toric PRK using an erodible mask is capable of treating compound myopic astigmatism with moderate success.
METHODS: A prospective study was performed on consecutive eyes having surface sequential toric PRK over a 4 month treatment period. Attempted astigmatism correction varied from 70 to 100%, depending on the power and axis of the cylinder. The myopic correction was adjusted so the combined treatment aim was emmetropia. Refraction, manual keratometry, corneal haze, and visual acuity data from preoperative and follow-up visits over 12 months were divided into various groups based on the preoperative refraction and analyzed.
RESULTS: Fifty-nine eyes from 48 patients had sequential toric PRK. Preoperatively, the mean spherical equivalent at glasses plane (SEGP) was -4.88 diopters (D) +/- 3.20 (SD) and the mean refractive cylinder, 2.02 +/- 1.04 D. The mean attempted cylinder correction was 1.87 D. At 12 months the mean SEGP was -0.02 +/- 0.67 D, which was not statistically significant from plano. The mean refractive cylinder was 0.84 +/- 0.84 D, which was statistically significantly different from zero cylinder power. There was a statistically significant correlation between the preoperative and the 12 month postoperative refractive cylinder powers. At 12 months, 34 of 43 eyes (79.1%) had an uncorrected visual acuity of 6/12 or better. While 2 eyes in one patient (4.7%) lost two lines of best corrected visual acuity, with a final acuity of 6/12 in each, no patient lost more than two lines.
CONCLUSION: The manifest refraction cylinder power is not fully corrected with the current treatment algorithms; however, surface sequential toric PRK using an erodible mask is capable of treating compound myopic astigmatism with moderate success.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app